CSIR Central

A lipidated bi-epitope vaccine comprising of MHC-I and MHC-II binder peptides elicits protective CD4 T cell and CD8 T cell immunity against Mycobacterium tuberculosis.

IR@IMTECH: CSIR-Institute of Microbial Technology, Chandigarh


Field	Value

Title	A lipidated bi-epitope vaccine comprising of MHC-I and MHC-II binder peptides elicits protective CD4 T cell and CD8 T cell immunity against Mycobacterium tuberculosis.

Creator	Rai, Pradeep K Chodisetti, Sathi Babu Maurya, Sudeep K Nadeem, Sajid Zeng, Weiguang Janmeja, Ashok K Jackson, David C Agrewala, J N

Subject	QR Microbiology

Description	The clinical trials conducted at Chingleput India suggest that BCG fails to protect against tuberculosis (TB) in TB-endemic population. Recent studies advocate that non-tuberculous mycobacteria and latent Mycobacterium tuberculosis (Mtb) infection interferes in the antigen processing and presentation of BCG in inducing protective immunity against Mtb. Thereby, indicating that any vaccine that require extensive antigen processing may not be efficacious in TB-endemic zones. Recently, we have demonstrated that the vaccine candidate L91, which is composed of lipidated promiscuous MHC-II binder epitope, derived from latency associated Acr1 antigen of Mtb is immunogenic in the murine and Guinea pig models of TB and conferred better protection than BCG against Mtb.

Publisher	Springer Nature

Date	2018-10-11

Type	Article PeerReviewed

Relation	https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-018-1653-x http://crdd.osdd.net/open/2143/

Identifier	Rai, Pradeep K and Chodisetti, Sathi Babu and Maurya, Sudeep K and Nadeem, Sajid and Zeng, Weiguang and Janmeja, Ashok K and Jackson, David C and Agrewala, J N (2018) A lipidated bi-epitope vaccine comprising of MHC-I and MHC-II binder peptides elicits protective CD4 T cell and CD8 T cell immunity against Mycobacterium tuberculosis. Journal of translational medicine, 16 (1). p. 279. ISSN 1479-5876